×
Skip to content
ShareCafe

  • Home
  • Shares
  • Advice
  • Wealth
    • Wealth Home
    • Product Profiles
  • Property
  • Video
  • Contributors
  • Community
  • About us
  • Facebook
  • Twitter
  • YouTube
  • RSS
Main Menu

Tag: KCN

Broker News

KCN – Macquarie rates the stock as Underperform

January 23, 2014 - by Broker News

Kingsgate posted a positive production result, featuring improvement at Chatree, solid production at Challenger and progress on development projects, the broker notes. Guidance was reiterated and the balance sheet has improved slightly. The increased share count leads to an 8% fall in forecast earnings and the target falls to $1.00 from $1.40.

Read More
Fn Arena News

Kingsgate's Shock Raising

February 23, 2012 - by Greg Peel

There were few major surprises in the interim earnings result of Kingsgate Consolidated ((KCN)), as underlying earnings of $33.8 million were only slightly below market expectations due primarily to higher costs during the period.

Read More
Broker News

KCN – RBS Australia rates the stock as Upgrade to Buy from Hold

September 16, 2011 - by Broker News

Target $9.13 (was $8.52). RBS Australia has revised commodity price forecasts and the changes have flowed through to revisions to earnings estimates and price targets across the resources sector.

Read More
Broker News

KCN – RBS Australia rates the stock as Hold

October 26, 2010September 5, 2018 - by Broker News

Kingsgate has embarked on a take-over spree, announcing its second acquisition target in as many weeks and with management suggesting a third one might not be far off. RBS analysts comment the bid for Chilean junior explorer Laguna Resources is immaterial but if successful the longer term upside could be "appealing".

Read More
Broker News

KCN – RBS Australia rates the stock as Buy

August 2, 2010 - by Broker News

The broker had been anticipating a reserve increase from Kingsgate to provide a 60% increase in mine life, but the actual announcement gives the broker more confidence in its figures. The broker sees further expansion ahead.

Read More
Broker News

KCN – Citi rates the stock as Buy, High Risk

July 22, 2010 - by Broker News

Q4 production is seen as solid coming in just ahead of Citi expectations.

Read More
Shares

Kingsgate Reassures Shareholders

December 10, 2007 - by Glenn Dyer

Gold miner and explorer Kingsgate Consolidates (KCN) said on Sunday that media reports early last week were incorrect and misleading when reporting on the company's mining applications in Bangkok.

Read More
Shares

Kingsgate In Trading Halt Amid Speculations

December 3, 2007 - by Glenn Dyer

Gold miner and explorer, Kingsgate Consolidated (KCN) fell by as much as 21% to $3.87 on Monday after the company requested a trading halt pending the release of an announcement.

Read More
Broker News

KCN – Aspect Huntley rates the stock as Upgrade to Accumulate from Hold

June 18, 2007 - by Broker News

Aspect Huntley has lifted its rating as the company conducts a feasibility study into the potential for lifting production at Chatree to 300koz annually.

Read More
Broker News

KCN – Aspect Huntley rates the stock as Downgrade to Hold

April 24, 2007 - by Broker News

Aspect Huntley’s downgrade reflects recent gains in the share price, which it suggests have come a bit early given the company has still not been granted additional leases around its Chatree operations.

Read More
Broker News

KCN – Aspect Huntley rates the stock as Upgrade to Speculative Buy

January 19, 2007 - by Broker News

The company sold a stake in Goldstar Resources (GDR) for a profit of around $9.5m, Aspect Huntley noting this improves its valuation on the stock by 20c to $4.80. This, combined with recent share price weakness, supports its move to upgrade its recommendation.

Read More
  • Inauguration Inflation
  • Lunch Report: Aussie market bounces back
  • Optimistic Investing Belies an Uncertain Outlook
  • The Unknown Unknowns
  • Australia…One Hour In…ASX up 67 points
  • ELD – Citi rates the stock as Buy
  • SUL – Credit Suisse rates the stock as Outperform
  • CGF – Morgans rates the stock as Hold

Subscribe to ShareCafe

The daily resource for hands-on investors. Market insights and investment ideas delivered free to your inbox.

Copyright 2020 Informed Investor Pty Ltd ABN 42 162 871 589. All rights reserved.
No portion of this website maybe reproduced, copied or in any way released without written permission.
Share Cafe is a Corporate Authorised Representative (001283561) of PacReef Asset Management Pty Ltd who holds an Australian Financial Services Licence (Number: 488045)

Terms of Service | Financial Services Guide | Privacy Policy | Contact | Advertise

DOWNLOAD RESEARCH REPORT

And a Door Opens Wide

Antisense Therapeutics’ lead drug sits at the nexus of two areas of drug development that are starting to grow dramatically in importance. One relates to its mode of action and the other to the type of drug it is. Combine that with management who know the drug very well and strong results in a trial in a horrible disease afflicting children, and you have the basis for true value creation.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Key.


DOWNLOAD RESEARCH REPORT

Fit for tough times; prepared for coal’s upswing

Terracom has counter-cyclically placed itself in a position to improve efficiency and margins plus pursue organic mine growth. Cashflows will further swell once currently depressed coal prices rebound. These assets appear undervalued compared to our Base Case $0.27/share NPV valuation of TER. TER has upside on management’s record of delivering new projects from currently controlled development assets and/or by opportunistically securing acquisitions.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Truck.

DOWNLOAD RESEARCH REPORT

A Laser-Like Focus on Adding Value

Since August 1st, Kazia Therapeutics has announced US Food & Drug Administration fast track status for one program & orphan drug and rare paediatric disease designation for another, while finishing the period by announcing a new trial for its cancer drug, paxalisib. Over the next nine months investors are likely to see six data readouts from five programs. How fast can a company go?

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Tree.